Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Contact us

1234 5678

PO Box 3787

South Brisbane QLD 4101

C1131003

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Open for recruitment

Trial summary

This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (>3 months and ≤12 months), or chronic (>12 months) ITP

Trial details

Short title

C1131003

Diagnosis

Immune Thrombocytopenia (ITP)

Phase

II

Locations

Investigators

Principal Investigators

Who can participate

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your healthcare provider if you are interested in this clinical trial.